All In Biotech

Drug Trial Radar · NCT07385547

Study to Evaluate if Exposure to Drug is Impacted in Participants With Renal Insufficiency

A Phase 1 Study to Assess the Effect of Renal Impairment on the Pharmacokinetics of GL0034

Last checked: Nov 19, 2026Latest source record: Mar 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

40

Planned (sponsor's estimate)

Start

Feb 25, 2026

Primary completion

Sep 2026

Study completion Sep 27, 2026

Sponsor

Sponsor type
Industry
First posted
Feb 4, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is an open-label, single-dose, Phase 1 clinical study designed to evaluate the effect of renal impairment on the pharmacokinetics (PK) of GL0034, a long-acting GLP-1 receptor agonist. Approximately 40 adult participants will be enrolled across four groups: normal renal function, moderate renal impairment, severe renal impairment without dialysis, and severe renal impairment with dialysis. Each participant will receive a single subcutaneous dose of GL0034. Blood samples will be collected for PK analysis. Secondary objectives include assessing safety and tolerability. The study will help determine whether renal impairment affects GL0034 exposure and inform dosing recommendations for patients with compromised renal function.

Conditions

  • Type II Diabetes Mellitus

Interventions

  • GL0034Drug

    Subcutaneous (SC) administration of a single dose of GL0034

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Single dose PK exposure parameters: Maximum concentration (Cmax)Time frame: From predose through 672 hours post-dose (multiple time points)
  2. Single dose PK exposure parameters: Area under the plasma concentration-time curve (AUC) from time zero to the time of the last quantifiable concentration (AUC0-t)Time frame: From predose through 672 hours post-dose (multiple time points)
  3. Single dose PK exposure parameters: AUC from time zero extrapolated to infinite time (AUC0-i)Time frame: From predose through 672 hours post-dose (multiple time points)

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Syneos Miami

    Miami, Florida · Not yet recruiting

  • Panax Clinical Research

    Miami Lakes, Florida · Recruiting

  • Orlando Clinical Research Center (OCRC)

    Orlando, Florida · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.